WallStreetZenWallStreetZen
Analyst Ranking
Bottom 3%
#4480 out of 4606 analysts
Average Return
-12.97%
Win Rate
30%26 out of 88
Risk vs Reward
Poor
Good

David Turkaly's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Icad IncICAD
+99.77%$8.88$17.74
2020-02-05 -
2021-02-05
Buy
Si Bone IncSIBN
+34.91%$12.69$17.12
2022-11-08 -
2023-11-07
Buy
Steris PLCSTE
+34.16%$114.74$153.94
2018-08-09 -
2019-08-09
Buy
Haemonetics CorpHAE
+34.12%$61.51$82.50
2021-11-10 -
2022-11-09
Buy
Lantheus Holdings IncLNTH
+26.13%$64.32$81.13
2023-11-03 -
2024-06-18
Buy

David Turkaly Analyst Color

Get additional color on David Turkaly's coverage of popular stocks

David Turkaly's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Haemonetics CorpHAE
6Buy$125.00+46.37%Maintains
a month ago
Steris PLCSTE
10Buy$265.00+22.40%Reiterates
a month ago
Paragon 28 IncFNA
4Buy$20.00+250.26%Maintains
a month ago
Si Bone IncSIBN
5Buy$32.00+158.27%Reiterates
a month ago
Orthopediatrics CorpKIDS
8Buy$50.00+67.00%Reiterates
a month ago
Integra Lifesciences Holdings CorpIART
10Buy$40.00+37.93%Maintains
a month ago
Tela Bio IncTELA
4Buy$15.00+195.28%Reiterates
3 months ago
Teleflex IncTFX
10Buy$285.00+41.03%Reiterates
4 months ago
Lantheus Holdings IncLNTH
5Buy$100.00+23.26%Reiterates
4 months ago
Zimmer Biomet Holdings IncZBH
10Buy$140.00+31.22%Maintains
7 months ago
Nevro CorpNVRO
5Buy$40.00+354.03%Maintains
a year ago
Neuronetics IncSTIM
3Buy$12.00N/AReiterates
a year ago
Axogen IncAXGN
3Buy$20.00N/AReiterates
a year ago
Icad IncICAD
4Buy$4.00N/AMaintains
a year ago
Apyx Medical CorpAPYX
1Buy$14.00N/AMaintains
3 years ago
Cognyte Software LtdCGNT
1Buy$5.00N/AInitiates Coverage On
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.